- Home
- STXS vs FENC Comparison
STXS vs FENC Comparison
Compare STXS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- FENC
- Stock Information
- Founded
- STXS 1990
- FENC 1996
- Country
- STXS United States
- FENC United States
- Employees
- STXS N/A
- FENC N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STXS Health Care
- FENC Health Care
- Exchange
- STXS Nasdaq
- FENC Nasdaq
- Market Cap
- STXS 151.3M
- FENC 156.9M
- IPO Year
- STXS 2004
- FENC 2001
- Fundamental
- Price
- STXS $1.98
- FENC $5.63
- Analyst Decision
- STXS
- FENC Strong Buy
- Analyst Count
- STXS 0
- FENC 2
- Target Price
- STXS N/A
- FENC $14.00
- AVG Volume (30 Days)
- STXS 428.1K
- FENC 77.1K
- Earning Date
- STXS 05-12-2025
- FENC 05-13-2025
- Dividend Yield
- STXS N/A
- FENC N/A
- EPS Growth
- STXS N/A
- FENC N/A
- EPS
- STXS N/A
- FENC N/A
- Revenue
- STXS $26,918,000.00
- FENC $47,538,000.00
- Revenue This Year
- STXS $34.90
- FENC $2.68
- Revenue Next Year
- STXS $58.64
- FENC $71.63
- P/E Ratio
- STXS N/A
- FENC N/A
- Revenue Growth
- STXS 0.55
- FENC 123.69
- 52 Week Low
- STXS $1.54
- FENC $3.96
- 52 Week High
- STXS $2.72
- FENC $10.07
- Technical
- Relative Strength Index (RSI)
- STXS 56.75
- FENC 49.40
- Support Level
- STXS $1.78
- FENC $5.51
- Resistance Level
- STXS $2.07
- FENC $5.75
- Average True Range (ATR)
- STXS 0.13
- FENC 0.33
- MACD
- STXS 0.04
- FENC 0.09
- Stochastic Oscillator
- STXS 82.08
- FENC 88.79
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.